webinar register page

Webinar banner
Pharma - Hematologic Cancers and Gene-based “Tumor Agnostic” Therapies
How much more mileage is in store for blood-based cancer survival rates, which have been increasing steadily in recent years? And what is being done about the flip side of this success, expressed in more treatment-related morbidities, disease relapse and higher incidence 2 of other malignancies?

Oct 26, 2022 11:00 AM in Eastern Time (US and Canada)

Webinar logo
* Required information


Astellas Pharma
Epizyme Inc.
Reshma Rangwala, MD, PhD
Chief Medical Officer @Karyopharm Therapeutics, Inc.
Dr. Rangwala brings more than a decade of experience in oncology and drug development to her role at Karyopharm. She was most recently the Chief Medical Officer at Aravive, where she led the clinical development of batiraxcept across multiple tumor types. Prior to Aravive, she served as Vice President, Medical, at Genmab where she led the clinical development program for a first-in-class antibody drug conjugate and managed clinical strategy, protocol development, data monitoring, data analysis, study report authoring, and biologic licensing application preparations. Prior to Genmab, she served as Executive Clinical Director at Merck & Co., where she was involved in the clinical development of KEYTRUDA in non-small cell lung cancer and gynecologic malignancies. Dr. Rangwala received her B.S. in Biology from Duke University and her M.D./Ph.D. from the University of Cincinnati College of Medicine.
Paramjit Kaur, PhD, MS
Asset Leader @Servier Pharmaceuticals
Pam Kaur PhD MS is the Asset Leader for Asparaginases at Servier Pharmaceuticals and has led the late stage management of the brand ASPARLAS since joining the company in July 2021. She is a global cross-functional leader with over 20 years of drug development spanning academic/hospital and industry experiences managing pre-clinical, translational and clinical programs including, early and late clinical development at Alcon Novartis, and EMD Serono - Merck KGaA. Previously, Pam led Combinations of the Immune-Oncology asset Bavencio at Merck KGaA, which included over 40 external alliances in her purview. Pam received both her Doctorate of Philosophy in Pharmacology and Neuroscience and Master of Science from University of North Texas Health Science Center.
Susan Pandya, MD
Vice President, Clinical Development and Head of Cancer Metabolism Global Development Oncology & Immuno-Onco @Servier Pharmaceuticals
Susan Pandya M.D. is the Head of Cancer Metabolism Global Development at Servier Pharmaceuticals. She is a passionate and innovative oncologist with over a decade of drug development experience. Prior, Susan led the clinical development of the first-in-class IDH inhibitors in Oncology indications with a high unmet need at Agios Pharmaceuticals. She has worked on developing pivotal programs from early through late stages, including one in IDH1 mutant cholangiocarcinoma, resulting in the submission a supplemental new drug application for ivosidenib and more recently the newly diagnosed IDH1 mutant AML leading to another regulatory submission and FDA approval of ivosidenib in combination with azacitidine. At Servier, her team leads the global Phase 3 development of vorasidenib, a brain penetrant dual mutant IDH1/2 inhibitor in malignant gliomas, directing the clinical biomarker strategy for these rare disease sub-types and overseeing the life cycle management of Oncaspar and Asparlas.